ClinicalTrials.gg
CompletedNCT07225829INFLAM MOTIONUpdated Oct 23, 2026

A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis

A Phase 2 interventional study of 4P004 and Placebo (NaCl 0.9%) in Knee Osteoarthritis and Synovitis of Knee, sponsored by 4Moving Biotech. Completed at 22 sites in 6 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by 4Moving Biotech · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2025, registered Sep 2025).
Updated Oct 23, 2026Now CompletedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 100 studies in Osteoarthritis, Knee with a site in Spain — 16 open to participants now, 19 under way, 3 of them phase 3. Osteoarthritis, Knee · Spain.

Enrollment
34th of 86
130 · median 100
Started
2025
with 1 other
Phase 2
10 of 100
none open now
Registered
91st of 100
by date

Among the 100 studies in Osteoarthritis, Knee with a site in Spain, this one is the 34th largest by enrollment of the 86 interventional ones that give a count, is one of 2 that started in 2025, is one of 10 in phase 2, and was the 91st registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

16 of the 100 studies in Osteoarthritis, Knee with a site in Spain are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies in Osteoarthritis, Knee with a site in Spain, or all of them as a file.
02

Study summary

This phase 2a trial is an international, multicenter, randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of one single intra-articular (IA) injection of 4P004 or placebo in:

  • patients between 40 and 80 years of age,
  • with synovitis and grade 2 to 4 osteoarthritis (OA) of the knee according to Kellgren and Lawrence (KL) classification.
03

Conditions studied

  • Knee Osteoarthritis
  • Synovitis of Knee

Keywords

  • OA
  • Knee OA
  • Liraglutide
  • Osteoarthritis
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who have the capacity to give and who are willing to comply with all trial related procedures and assessments.
  • Participants between 40 and 80 years of age.
  • Female participant of (defined as any woman unless for at least one year or surgically sterile) must use highly effective methods of as defined in the protocol. Highly effective contraceptive measures must be continued throughout the trial until the final visit.
  • Bodyweight > 40 kg.
  • (BMI) ≥ 18.5 and ≤ 35.
  • Ambulatory (single assistive devices such as canes allowed).
  • Widespread Pain Index (WPI) ≤ 4.
  • Pain NRS (0-10) \< 4 in the contralateral knee.
  • History of OA-related pain of the TK for at least 6 months.
  • Moderate to severe pain of the TK the majority of days during the last 3 months as per participant's judgement.
  • Moderate to severe pain of the TK on the WOMAC Pain subscale prior to the Randomization visit (V2) complying with: a) Complete WOMAC Pain diary for at least 7 of the last 10 days prior to V2 (including V2/D1 rating which is mandatory), and b) Diary reported WOMAC Pain between 5 and 9 for at least 7 of the last 10 days.
  • History of insufficient pain relief, intolerance, or to NSAIDs, and at least a history of insufficient pain relief from at least one of the following therapies: a) Acetaminophen/paracetamol, b) Opioids including tramadol, or c) , hyaluronate IA injections (efficacy less than 3 months according to the patient).
  • KL grade 2 to 4 on the Schuss radiograph.
  • Predominant femorotibial OA based on the OA Research Society International. (OARSI) Atlas reading (Altman \& Gold, 2007).
  • Presence of synovitis in the TK assessed locally using PDUS, and synovial thickness of ≥ 5 mm evaluated through a longitudinal view of the suprapatellar pouch and axial views of the medial and lateral patellofemoral pouches.
  • Negative urine drug screen (performed locally): amphetamines, barbiturates, cocaine.
  • CE-MRI Central reading to confirm synovitis with a synovial Semi-Quantitative (SQ) ≥ 9 or a SQ score ≥7 with at least one site with a score ≥ 2.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women.
  • Significant malalignment of anatomical axis (medial angle formed by the femur and tibia) of the TK (varus > 10°, valgus > 10°) by radiography.
  • Secondary OA such as joint dysplasia, aseptic osteonecrosis, joint infection, acromegaly, Paget disease, hemochromatosis, joint crystal disease or any inflammatory joint disease.
  • Any known active infections including skin infections at the site injection or increased predisposition for the development of infections.
  • Any partial knee replacement of the TK.
  • Acute fracture or IA trauma to the TK within 12 months prior to the screening visit.
  • Major knee surgery performed within the previous 12 months or planned during the trial.
  • Arthroscopy of the TK within 6 months prior to the screening visit.
  • Presence of any painful conditions that could confound accurate assessment of pain from OA in the TK, such as fibromyalgia, peripheral neuropathy or vascular insufficiency.
  • Treatment with systemic (other than IA) at a dose greater than 10 mg prednisone or the equivalent per day for more than 7 days within 4 weeks prior to the screening visit.
  • Treatment of the TK with any IA injection (including corticosteroids, hyaluronic acid derivatives, Rich Plasma….) within 24 weeks prior to the screening visit.
  • Any treatment with glucosamine, chondroitin sulfate, or other nutraceuticals with potential activity on OA within the previous 3 months prior to the screening visit.
  • Treatment with duloxetine for OA (allowed if given for depressive disorders at stable dose since at least 3 months before V1).
  • Any significant psychiatric illness unless well controlled since at least 6 months.
  • Current treatment with combination of insulin and liraglutide (Xultophy®) or with GLP-1 agonist administered once a week (semaglutide, dulaglutide).
  • High-risk of bleeding.
  • Congestive Heart Failure stage III or IV in the classification.
  • History or current diagnosis of ECG abnormalities indicating significant safety risk (such as ischemia, significant cardiac arrhythmias).
  • Glycemia \< 4.4 mmol/L (or 80 mg/dL) at screening.
  • abnormal laboratory test at screening, in particular: \<10 g/dL, white blood cell \<3000/µL (3.0 Giga/L), \<1000/µL (1.0 Giga/L), platelets count \<100,000/µL (100 Giga/L), or aspartate aminotransferase >2.5 (ULN), total >1.5 ULN, lipasemia >1 ULN.
  • Estimated (eGFR) \<60 mL/min/1.73 m2, using Chronic Kidney Disease - EPIdemiology (CKD EPI) 2021 Formula.
  • Any other abnormal laboratory results that the Investigator believes should preclude the subject's participation in the trial.
  • History of to IMP or (liraglutide or disodium phosphate dihydrate, propylene glycol, phenol).
  • Any for MRI (cardiac pacemaker, deep brain stimulators, intraocular metal, cerebral aneurysm clips, recent stents, cochlear implants, neurostimulators and implantable pumps) or inability to undergo MRI (e.g., body size, leg not fitting in the coil, claustrophobia).
  • History of hypersensitivity reactions to a gadolinium-based contrast agent.
  • Any CE-MRI Central reading additional diagnoses: posterior meniscal root tears, subchondral insufficiency fractures, osteonecrosis, malignant bone marrow infiltration, solid tumours, and traumatic fracture or bone bruise using ROAMES (Roemer et al., 2020).
  • Previous participation in clinical research with a disease-modifying OA drug during the last 2 years.
  • Participation in an interventional clinical research trial within 3 months before screening.
  • Participants who, in the investigator's judgement, are at risk of falling.
  • Participants with a history, or current diagnosis, of pancreatitis, thyroid cancer (including medullary thyroid carcinoma), multiple endocrine neoplasia type-2 (MEN2), diabetic ketoacidosis, type-1 diabetes mellitus (T1DM), inflammatory bowel disease, or diabetic gastroparesis.
  • Participants currently, or within the last 10 days, taking any anticoagulant treatment.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    4P004 (2mL)

    One IA injection in the knee of 4P004 (2mL) on the day of randomization

    Drug: 4P004

  • Placebo comparator
    Placebo (NaCl 0.9% 2mL)

    One IA injection in the knee of Placebo (NaCl 0.9% 2mL) on the day of randomization

    Drug: Placebo (NaCl 0.9%)

Interventions

  • Drug4P004

    Single intra-articular injection in the knee joint

    Also known as: Liraglutide

  • DrugPlacebo (NaCl 0.9%)

    Single intra-articular injection in the knee joint

06

What researchers measure

Primary outcomes

  1. Change from Baseline at Week 4 in the weekly average of Target Knee (TK) daily pain intensity using the WOMAC (Western Ontario and McMaster Universities Arthritis Index) Pain subscore

    The WOMAC is a questionnaire widely used in the evaluation of knee osteoarthritis. It contains 24 items measuring 3 subscales: physical function (17 items), pain (5 items), and stiffness (2 items). Scores are calculated for each subscale and summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. The sum of the scores for all three subscales gives a total WOMAC score. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.

    Time frame: Baseline and Week 4

Secondary outcomes

  1. Change from Baseline at Week 2, Week 6, Week 8, Week 10 and Week 12 in the weekly average of TK (Target Knee) daily pain intensity using the WOMAC (Western Ontario and McMaster Universities Arthritis Index) Pain subscore

    The WOMAC is a questionnaire widely used in the evaluation of knee osteoarthritis. It contains 24 items measuring 3 subscales: physical function (17 items), pain (5 items), and stiffness (2 items). Scores are calculated for each subscale and summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. The sum of the scores for all three subscales gives a total WOMAC score. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.

    Time frame: Baseline, Week 2, Week 6, Week 8, Week 10 and Week 12

  2. Change from Baseline at Week 2, Week 4, Week 8 and Week 12 in the NRS (Numeric Rating Scale) pain (scale 0-10) in a nominated pain aggravating activity

    The numeric rating scale (NRS) is a pain screening tool, commonly used to assess pain severity at that moment in time, using a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable.

    Time frame: Baseline, Week 2, Week 4, Week 8 and Week 12

  3. Change from Baseline at Week 2, Week 4, Week 8 and Week 12 in WOMAC (Western Ontario and McMaster Universities Arthritis Index) subscores and total score

    The WOMAC is a questionnaire widely used in the evaluation of knee osteoarthritis. It contains 24 items measuring 3 subscales: physical function (17 items), pain (5 items), and stiffness (2 items). Scores are calculated for each subscale and summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. The sum of the scores for all three subscales gives a total WOMAC score. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.

    Time frame: Baseline, Week 2, Week 4, Week 8 and Week 12

  4. Change from Baseline at Week 2, Week 4, Week 8 and Week 12 in the Patient Global Assessment of Osteoarthritis (PGA-OA)

    The PGA-OA is a 1-item questionnaire designed to assess the participant's impression of disease severity adapted from Guy et al., 1976, to the specific disease as a Patient-reported Outcome measurement "Considering all the ways your knee osteoarthritis affects you, how are you doing these last seven days ?". PGA-OA is measured on a 5-point Likert scale, with higher scores indicating worse symptoms (1= "very good" to 5 = "very poor").

    Time frame: Baseline, Week 2, Week 4, Week 8 and Week 12

  5. Percentage (%) of OMERACT-OARSI Responders at Week 2, Week 4, Week 8 and Week 12

    Time frame: Week 2, Week 4, Week 8 and Week 12

  6. Incidence and severity of TEAEs (Treatment-Emergent Adverse Events) during the trial

    Time frame: From randomization to end of trial, up to 12 weeks

  7. Absolute changes from Baseline in clinical laboratory assessment - hematology parameter: total blood cells count (in cell/L)

    Time frame: From randomization to end of trial (up to 12 weeks)

  8. Absolute changes from Baseline in clinical laboratory assessments - hematology parameter: hemoglobin (in g/L)

    Time frame: From randomization to end of trial (up to 12 weeks)

  9. Absolute changes from Baseline in clinical laboratory assessment - blood chemistry: AST (in U/L)

    Time frame: From randomization to end of trial (up to 12 weeks)

  10. Absolute changes from Baseline in clinical laboratory assessment - blood chemistry: ALT (in U/L)

    Time frame: From randomization to end of trial (up to 12 weeks)

  11. Absolute changes from Baseline in clinical laboratory assessment - blood chemistry: lipase (in U/L)

    Time frame: From randomization to end of trial (up to 12 weeks)

  12. Absolute changes from Baseline in clinical laboratory assessment - blood chemistry: fasting glycemia (in mmol/L)

    Time frame: From randomization to end of trial (up to 12 weeks)

  13. Absolute changes from Baseline in clinical laboratory assessment - blood chemistry: total bilirubin (in umol/L)

    Time frame: From randomization to end of trial (up to 12 weeks)

  14. Absolute changes from Baseline in Vital signs: systolic and diastolic blood pressure (BP)

    Time frame: From randomization to end of trial (up to 12 weeks)

  15. Absolute changes from Baseline in Vital signs: pulse rate

    Time frame: From randomization to end of trial (up to 12 weeks)

07

Study locations

22 sites
  • Tucson Orthopaedic Institute
    Tucson, Arizona 85712-2805, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • Skylight Health Research Burlington
    Burlington, Massachusetts 01803, United States
  • Durham Bone and Joint Specialists
    Ajax, Canada
  • SJHC London Rheumatology Centre
    London, Canada
  • G.R.M.O. (Groupe de recherche en maladies osseuses) Inc
    Québec, Canada
  • Parker Institute Bispebjerg, Frederiksberg Hospital
    Frederiksberg, Denmark
  • Sanos Clinic Herlev
    Herlev, Denmark
  • CHU Montpellier
    Montpellier, France
  • ChU de Nice
    Nice, France
  • Hôpital Cochin
    Paris, France
  • Hôpital Lariboisière
    Paris, France
  • Centre Hospitalier Universitaire CHU de Reims - Hopital Maison Blanche
    Reims, France
  • Care Access Kraków
    Krakow, Poland
  • Centrum Medyczne Reuma Park
    Warsaw, Poland
  • MICS Centrum Medyczne Warszawa
    Warsaw, Poland
  • Clínica Gaias Santiago
    A Coruña, 15702, Spain
  • Complejo Hospitalario Universitario de A Coruna - Hospital Universitario de A Coruna
    A Coruña, Spain
  • HLA Clínica Vistahermosa
    Alicante, Spain
  • Corporacio Sanitaria Parc Tauli - Hospital de Sabadell
    Sabadell, Spain
  • Clinica Nuestra Senora de la Esperanza
    Santiago de Compostela, Spain
  • Hospital Quirónsalud Sagrado Corazón
    Seville, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Aug 2026, 14 months.

Of 58 industry-sponsored phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 25. This study's 14 months is below that.

Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Nov 10, 2025
StartActual
Jun 17, 2025
Primary completionActual
Aug 31, 2026
CompletionActual
Oct 19, 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 23, 2026
Study completion
Oct 28, 2026→Oct 19, 2026 (actual)
Oct 23, 2026
Enrollment
129 (estimated)→130 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Active, not recruiting→Completed
    Study completion Oct 28, 2026→Oct 19, 2026 (now actual)
    Enrollment 129 (estimated)→130 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07225829
Lead sponsor
4Moving Biotech
Responsible party
Sponsor
First posted
Nov 10, 2025
Start date
Jun 17, 2025
Primary completion
Aug 31, 2026
Completion
Oct 19, 2026
Last update
Oct 23, 2026

Study contacts

Francis Berenbaum, MD, PhD
study chair · 4

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion